BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that George D. Yancopoulos, M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded Columbia College’s Alexander Hamilton Medal, the highest honor awarded to a member of the Columbia College community for distinguished service and accomplishment in any field of endeavor.

SHEPHERD and its founder David Hysong today announced it has named Catharine Young, Ph.D., as the Executive Director of the SHEPHERD Foundation.

Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY™ (diroximel fumarate), a new FDA-approved treatment for relapsing forms of multiple sclerosis (MS), compared to TECFIDERA® (dimethyl fumarate).

Intent Solutions, an Atlanta-based company that provides technology to secure medications and track prescription adherence, is collaborating with AT&T to integrate LTE-M cellular technology into the new release of Intent’s tad™ dispensing system.

NextGate, the global leader in healthcare enterprise identification, announced today it has been recognized as a ‘Notable Next-Generation Enterprise Master Patient Index (EMPI) Vendor’ in a new report from Gartner, Inc.

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced today that it has made another high-profile appointment.

Aesthetic treatment resource RealSelf.com reveals the year’s most popular nonsurgical and surgical cosmetic procedures, according to consumer research patterns

Medable Inc., a leading provider of a digital trials platform that connects patients, sites and clinical trial teams, today announced its participation at the American Heart Association (AHA) Health Tech & Innovation Summit on November 16-18, in Philadelphia, Pennsylvania.

Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen (approx. $26 Million) at Series B round, bringing its total financial backing to 3.8 Billion yen (approx. $35 Million) since it was founded in 2015.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (